Clearsynth’s Post

View organization page for Clearsynth, graphic

16,023 followers

Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic leukemia, has proven high efficacy and safety in different hematological diseases, particularly in chronic lymphocytic leukemia (CLL), and also in AML. Explore reference standards of Venetoclax on https://lnkd.in/dDziZDA2 Need assistance finding your product? Email us at sales@clearsynth.com for prompt support. #Impurities #StableIsotopes #Pharmacokinetics #Pharmacodynamics #clinicalresearch #clinicaltrials #drugdiscovery #drugdevelopment #fda #fdaapproval #usfda #lcms

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics